All Products
Men Care
Women Care
Sexual Wellness
Herbal & Homeopathy
Baby & Mom Care
Personal Care
Revira 1gm
Tablet
Pack Size :
6 Tablet x 1 Strip
Generics :
Valacyclovir
Manufacturer :
Square Pharmaceuticals Ltd.
Best Price *
TK
451.32
* Delivery will be done in Dhaka city only.
More Information About - Revira 1gm
Description
Generic Name
ValacyclovirPrecaution
Patient at risk of dehydration. Renal impairment. Pregnancy and lactation. Patient Counselling Avoid sexual intercourse when symptoms of genital herpes are present. Monitoring Parameters Monitor renal, hepatic and haematological functions. Lactation: Drug excreted in breast milk; use with cautionIndication
Genital herpes, Herpes zoster, Herpes labialis, CMV infectionsContra Indication
Hypersensitvity to valaciclovir, aciclovir.Dose
N/ASide Effect
>10% Headache (14-35%),Neutropenia (<18%),Elevated aspartate transaminase (AST) (2-16%),Nasopharyngitis (<16%),Nausea (6-15%),Elevated alanine transaminase (ALT) (<14%),Abdominal pain (2-11%) 1-10% Dysmenorrhea (1-8%),Depression (<7%),Arthralgia (<1-6%),Vomiting (<1-6%),Dizziness (2-4%),Rash (<8%),Rhinorrhea (<2%),Thrombocytopenia (<3%),Leukopenia (<1%) <1% Agitation,Aggression,Alopecia,Confusion,Erythema multiforme,Hypertension,Tachycardia,Tremor,Visual disturbances Potentially Fatal: Hepatitis; renal failure; blood dyscrasias; thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.Pregnancy Category
Name : Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.Mode of Action
Valaciclovir is the L-valine ester of aciclovir. A prodrug, it is rapidly converted to aciclovir by intestinal and hepatic metabolism. Aciclovir inhibits DNA synthesis and viral replication and has antiviral activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella-zoster virus.Interaction
Increased risk of renal failure w/ nephrotoxic drugs (e.g. aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus). Probenecid and cimetidine may increase peak plasma concentrations and AUC of aciclovir.Pregnancy Category Note
Pregnancy Clinical data over several decades with valacyclovir and its metabolite, acyclovir, in pregnant women, have not identified a drug associated risk of major birth defects; there are insufficient data on use of valacyclovir regarding miscarriage or adverse maternal or fetal outcomes; there are risks to fetus associated with untreated herpes simplex during pregnancy Risk of neonatal HSV infection varies from 30% to 50% for genital HSV acquired in late pregnancy (third trimester), whereas with HSV acquisition in early pregnancy, risk of neonatal infection is about 1%; a primary herpes occurrence during first trimester of pregnancy has been associated with neonatal chorioretinitis, microcephaly, and, in rare cases, skin lesions; in very rare cases, transplacental transmission can occur resulting in congenital infection, including microcephaly, hepatosplenomegaly, intrauterine growth restriction, and stillbirth Co-infection with HSV increases risk of perinatal HIV transmission in women who had a clinical diagnosis of genital herpes during pregnancy Animal data In animal reproduction studies, no evidence of adverse developmental outcomes was observed with valacyclovir when administered to pregnant rats and rabbits at system exposures (AUC) 4 (rats) and 7 (rabbits) times human exposure at maximum recommended human dose (MRHD) Lactation Although there is no information on presence of drug in human milk, its metabolite, acyclovir, is present in human milk following oral administration of drug; based on published data, a 500-mg maternal dose twice daily would provide a breastfed child with an oral acyclovir dosage of approximately 0.6 mg/kg/day; there is no data on effects of drug on breastfed child or on milk production Consider developmental and health benefits of breastfeeding along with mother?s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal conditionAdult Dose
Oral Herpes zoster (shingles) Adult: 1 g tid for 7 days. Immunocompromised patients: Continue treatment for a further 2 days after crusting of lesions. Herpes simplex infections of skin and mucous membranes; Genital herpes Adult: 500 mg bid for 3-5 days for recurrent episodes or up to 10 days for initial episodes. Immunocompromised patients: 1 g bid for at least 5 days for recurrent episodes or up to 10 days for initial episodes. Prophylaxis of cytomegaloviral infections in immunocompromised patients Adult: 2 g 4 times daily, begin as soon as possible post-transplant and usually continued for 90 days. Herpes labialis Adult: 2 g 12 hrly for 1 day. Suppression of recurrent herpes simplex Adult: 500 mg daily as a single or in 2 divided doses. Immunocompromised patients: 500 mg bid. Treatment is re-evaluated after 6-12 mth of therapy.Child Dose
Herpes simplex infections of skin and mucous membranes; Genital herpes Child: >12 yr: 500 mg bid for 3-5 days for recurrent episodes or up to 10 days for initial episodes. Immunocompromised patients: 1 g bid for at least 5 days for recurrent episodes or up to 10 days for initial episodes. Prophylaxis of cytomegaloviral infections in immunocompromised patients Child: >12 yr: 2 g 4 times daily, begin as soon as possible post-transplant and usually continued for 90 days. Herpes labialis Child: >12 yr: 2 g 12 hrly for 1 day. Suppression of recurrent herpes simplex Adult: Child: >12 yr: 500 mg daily as a single or in 2 divided doses. Immunocompromised patients: 500 mg bid. Treatment is re-evaluated after 6-12 mth of therapy. Chickenpox <2 years: Safety and efficacy not established >2 years: 20 mg/kg PO q8hr for 5 days; not to exceed 1 g PO q8hrRenal Dose
Herpes labialis CrCl 30-49 mL/min: 1 g PO q12hr for 1 day CrCl 10-29 mL/min: 500 mg PO q12hr for 1 day CrCl <10 mL/min: 500 mg PO once Herpes zoster CrCl 30-49 mL/min: 1 g PO q12hr CrCl 10-29 mL/min: 1 g/day PO CrCl <10 mL/min: 500 mg/day PO Genital herpes (initial episode) CrCl 10-29 mL/min: 1 g/day PO CrCl <10 mL/min: 500 mg/day PO qDay Genital herpes (recurrent episodes)(suppressive therapy, immunocompetent patients) CrCl <29 mL/min: 500 mg/day POAdministration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.
Others Product
In Stock
In Stock
In Stock
In Stock
